

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1 Name and Address of Company

Med BioGene Inc.
598 East Kent Avenue South
Vancouver, BC
V5X 4V6

(the “Company”)

Item 2 Date of Material Change

March 2, 2015

Item 3 News Release

The news release was disseminated on March 2, 2015 through the facilities of Marketwired, and subsequently filed on SEDAR.

Item 4 Summary of Material Change

The Company announced that Ms. Shumsheer Sidhu has accepted an invitation to join the board of directors.

Item 5 Full Description of Material Change

5.1 - Full Description of Material Change

See attached news release dated March 2, 2015, which news release, including the forward-looking statement caution contained therein, is incorporated herein by reference.

5.2 - Disclosure for Restructuring Transactions

Not applicable

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7 Omitted Information

Not applicable

Item 8 Executive Officer

For further information, contact:

Iain Weir-Jones
Chief Executive Officer
Telephone: 604-732-7332

Item 9 Date of Report

March 3, 2015

**MED BIOGENE INC.
598 East Kent Avenue South
Vancouver, BC V5X 4V6**

NEWS RELEASE

APPOINTMENT OF NEW DIRECTOR

Vancouver, B.C., March 2, 2015 – Med BioGene Inc. (“MBI” or the “Company”) (TSXV: MBI) wishes to announce that Ms. Shumsheer Sidhu, B.Sc., has accepted the invitation of the Company’s Directors to join the Board. Ms. Sidhu is a graduate of the University of British Columbia, and is both a CMA and CPA. Since graduation she has worked in the health care sector in a financial management capacity. She is currently the Finance Manager at NeuroDevNet, the first Trans-Canada initiative dedicated to studying children’s brain development.

Ms. Sidhu has been a shareholder of the Company since 2013 and has a substantial interest in the long term growth of this Company.

This appointment is in accordance with the previously stated policy of the Company to diversify the management and Board by involving representatives of the shareholders at the Board level, and to become more responsive to the concerns of the shareholders at large. Ms. Sidhu shares this objective and will become a member of the Company’s Audit Committee under the Chairmanship of David Diebolt, CA.

In accordance with the policy outlined before the last Annual General Meeting, Ms. Sidhu has agreed to forego Director’s fees until the Company’s GeneFX Lung™ has been commercialized and positive cash flow has been achieved. The Company hopes to announce commercialization in Q4 2015 and is working with its development partner Helomics to make this a reality.

About Med BioGene Inc.

MBI is a life science company based in Vancouver, British Columbia that is currently focused on managing the license and rights to GeneFX Lung™, a prognostic genomic based test procedure. MBI’s common shares are listed for trading on the Exchange. For more information, please visit www.medbiogene.com

For further information contact:

Iain Weir-Jones, Chief Executive Officer and Chairman of the Board of Directors
iainw@medbiogene.com
www.medbiogene.com

This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable Canadian and United States legislation. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include those risks set out in the Company’s public documents filed on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release